- Home
- WOR vs PTGX Comparison
WOR vs PTGX Comparison
Compare WOR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOR
- PTGX
- Stock Information
- Founded
- WOR 1955
- PTGX 2006
- Country
- WOR United States
- PTGX United States
- Employees
- WOR N/A
- PTGX N/A
- Industry
- WOR Aerospace
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- WOR Consumer Discretionary
- PTGX Health Care
- Exchange
- WOR Nasdaq
- PTGX Nasdaq
- Market Cap
- WOR 3.1B
- PTGX 2.9B
- IPO Year
- WOR N/A
- PTGX 2016
- Fundamental
- Price
- WOR $58.95
- PTGX $48.56
- Analyst Decision
- WOR Buy
- PTGX Strong Buy
- Analyst Count
- WOR 3
- PTGX 8
- Target Price
- WOR $57.00
- PTGX $66.50
- AVG Volume (30 Days)
- WOR 263.3K
- PTGX 789.1K
- Earning Date
- WOR 06-24-2025
- PTGX 05-06-2025
- Dividend Yield
- WOR 1.15%
- PTGX N/A
- EPS Growth
- WOR N/A
- PTGX N/A
- EPS
- WOR 1.21
- PTGX 0.86
- Revenue
- WOR $1,154,679,000.00
- PTGX $207,801,000.00
- Revenue This Year
- WOR N/A
- PTGX N/A
- Revenue Next Year
- WOR $3.75
- PTGX $50.30
- P/E Ratio
- WOR $48.49
- PTGX $55.04
- Revenue Growth
- WOR N/A
- PTGX N/A
- 52 Week Low
- WOR $37.88
- PTGX $27.00
- 52 Week High
- WOR $61.71
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- WOR 59.51
- PTGX 59.32
- Support Level
- WOR $57.96
- PTGX $45.43
- Resistance Level
- WOR $59.61
- PTGX $46.80
- Average True Range (ATR)
- WOR 1.07
- PTGX 1.50
- MACD
- WOR -0.49
- PTGX 0.35
- Stochastic Oscillator
- WOR 30.23
- PTGX 77.20
About WOR Worthington Enterprises Inc.
Worthington Enterprises Inc is a designer and manufacturer of products sold to consumers, through retail channels, in the tools, outdoor living and celebrations market categories as well as a wide array of specialized building products that serve customers in the residential and non-residential construction markets, including ceiling suspension systems and light gauge metal framing products, as well as wholly-owned and consolidated operations that produce pressurized containment solutions for heating, cooking and cooling applications, among others. It operates under two reportable operating segments: Consumer Products and Building Products. It derives majority of the revenue from Building Products segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.